No abstract available.
Coronary Restenosis*

We report a case of in-stent restenosis due to the fracture of a sirolimus-eluting stent, which was confirmed by intravascular ultrasound. It can be suggested that a stent fracture is an important cause of restenosis in this era of drug-eluting stents.
Coronary Restenosis ; Drug-Eluting Stents* ; Stents ; Ultrasonography

The efficacy of beta and gamma emitters in reducing clinical and angiographic restenosis in patients with in-stent restenosis has been confirmed by a number of studies. This review is intended to give an overview of the individual trials, summarize pertinent lessons that have been learned and give insight into the future of intracoronary radiation. The encouraging results from the clinical trials have established vascular brachytherapy as a standard of care for patients with in-stent restenosis.
Brachytherapy ; Coronary Restenosis ; Humans ; Standard of Care ; Stents

Coronary Restenosis ; pathology ; Fibroblasts ; metabolism ; pathology ; Fibrosis

Coronary Restenosis ; Drug-Eluting Stents ; Humans

Constriction, Pathologic ; Coronary Restenosis ; Humans ; Inflammation ; Stents

Angioplasty, Balloon, Coronary ; Coronary Restenosis ; therapy ; Humans ; Stents

Angioplasty, Balloon, Coronary ; Coronary Restenosis ; Humans ; Practice Guidelines as Topic

Angioplasty, Balloon, Coronary ; Coronary Restenosis ; therapy ; Drug-Eluting Stents ; Humans

BACKGROUND AND OBJECTIVES: The optimal treatment for in-stent restenosis(SR) s controversial, although intracoronary radiation therapy(CRT) as provided the most consistent results to date. This study was designed to assess the early and late angiographic results, and to find independent predictors of recurrent restenosis, following cutting balloon angioplasty(BA) or ISR. SUBJECTS AND METHODS: Eighty patients(7 lesions) ith first time ISR underwent CBA and systematic follow-up(U) ngiography. A conventional balloon was used before, or after, the CBA, if required. ICRT was used in 18 lesions(1%). A multivariate logistic regression analysis was performed.(why?) RESULTS: he ISR was focal(n=2, 37%), diffuse or proliferative(n=1, 58%) nd occlusive(n=4, 5%). Procedural success was achieved in all 87 lesions(00%). No significant edge dissection occurred. The pre- and post-procedural diameter stenoses(S) ere 81.5+/-10.8% and 6.7+/-6.0%, respectively, and the pre- and post-procedural MLD(efine MLD?) .71+/-0.44 mm and 2.85+/-0.32mm, respectively, with 2.14+/-0.44mm of acute gain. A FU angiography was performed in 54(8%) f the 69 lesions treated with CBA alone. The overall angiographic restenosis rate was 24%(3/54), with 9%(/22) n the focal ISR and 34%(1/32) n the diffuse or occlusive ISR. The FU DS and MLD were 32.0+/-23.4% and 2.1+/-0.7mm, respectively, with 0.79+/-0.69mm of late loss. The length of a restenotic lesion(R 12.2, 95% CI:1.3-115.2, p=.0286) as an independent predictor of recurrent restenosis. CONCLUSION: CBA is a simple and efficient first line treatment for ISR, with an acceptable restenosis rate, and the length of a restenotic lesion is an independent predictor of recurrent restenosis. In diffuse or occlusive ISR, more definite treatment modalities, such as ICRT combined with CBA or debulking techniques, might be required to reduce recurrent restenosis.
Angiography ; Angioplasty ; Angioplasty, Balloon* ; Coronary Restenosis ; Logistic Models ; Stents